Paying for performance (P4P) provides financial incentives for providers to increase the use and quality of care. P4P can affect health care by providing incentives for providers to put more effort into specific activities, and by increasing the amount of resources available to finance the delivery ...of services. This paper evaluates the impact of P4P on the use and quality of prenatal, institutional delivery, and child preventive care using data produced from a prospective quasi-experimental evaluation nested into the national rollout of P4P in Rwanda. Treatment facilities were enrolled in the P4P scheme in 2006 and comparison facilities were enrolled two years later. The incentive effect is isolated from the resource effect by increasing comparison facilities’ input-based budgets by the average P4P payments to the treatment facilities. The data were collected from 166 facilities and a random sample of 2158 households. P4P had a large and significant positive impact on institutional deliveries and preventive care visits by young children, and improved quality of prenatal care. The authors find no effect on the number of prenatal care visits or on immunization rates. P4P had the greatest effect on those services that had the highest payment rates and needed the lowest provider effort. P4P financial performance incentives can improve both the use of and the quality of health services. Because the analysis isolates the incentive effect from the resource effect in P4P, the results indicate that an equal amount of financial resources without the incentives would not have achieved the same gain in outcomes.
more
Lessons from three African Countries.
Achieving Health for All, and in particular universal health coverage (UHC), will not happen without fully functioning basic water, sanitation and hygiene (WASH) services in all health care facilities. Such services are needed to provide quality care, ensure ad...herence to infection prevention and control (IPC) norms and standards and guarantee that facilities are able to provide environments that respect the dignity and human rights of all care seekers, especially mothers, newborns and children. WHO undertook a series of national situational analyses in three countries (Ghana, Ethiopia and Rwanda) to understand current barriers to change, accountability structures and measures to strengthen WASH in health care facilities and more broadly, the quality of health service delivery.
more
Working Document, September 2017
Euro Surveill. 2016;21(12):pii=30174. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.12.30174
The World Health Organization's fourth Country Cooperation Strategy 2022-2026 is an outcome of a consultative process with inputs from the Ministry of Health, various agencies in the health sector, and other relevant stakeholders. It has been developed to provide strategic direction and support towa...rd achieving the priorities of the Government of the Kingdom of Eswatini.
It is designed to support the strengthening of health systems and services toward the attainment of Universal Health
Coverage (UHC) and the Sustainable Development Goals targets. The CCS 2022-2026 also presents the collaborative
agenda between the Kingdom of Eswatini and the three levels of WHO, aligns with the strategic priorities of WHO’s
13th General Programme of Work (2019 – 2025), as well as Eswatini’s United Nations Sustainable Development Cooperation Framework (UNSDCF) 2021-2025
more
Frontiers in Pediatrics | www.frontiersin.org
1 April 2019 | Volume 7 | Article 159
The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessment made by an external group of experts convened as members of the Guideline Development Group. Moreover, these guidelines focus on interventions speci...fic to preventing transmission of Mycobacterium tuberculosis bridging with the core components of infection prevention and control programmes at the national and acute health care facility level
more
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.